Sa. Watson et al., THERAPEUTIC EFFECT OF THE MATRIX METALLOPROTEINASE INHIBITOR, BATIMASTAT, IN A HUMAN COLORECTAL-CANCER ASCITES MODEL, British Journal of Cancer, 74(9), 1996, pp. 1354-1358
The matrix metalloproteinase inhibitor batimastat was administered to
a human colorectal cancer ascites model, which was initiated by inject
ion of C170HM(2) cells into the peritoneal cavity of sCID mice and res
ulted in solid tumour deposits and ascites formation. The cell line ex
pressed both the 72 and 92 kDa forms of gelatinase by zymography. Bati
mastat administered from day 0 (40 mg kg(-1)) reduced the volume of as
cites to 21% of control in mice treated from day 0 (P < 0.002) but not
day 10. Formation of solid peritoneal deposits was significantly redu
ced to 77% of vehicle control when batimastat was administered From da
y 0 (P<0.01) and 69% of control when administered from day 10 (P < 0.0
5). Thus, batimastat has the ability to reduce the volume of ascites f
orming in SCID mice injected intraperitoneally with the human colorect
al cell line, C170HM(2), when administered from day 0 but not from day
10. Solid peritoneal tumour deposits were significantly reduced in bo
th treatment groups, highlighting the therapeutic potential of batimas
tat in this clinical condition.